Abstract
Purpose
TO evaluate the efficacy and safety of a toric implantable Collamer lens (Visian TICL®) for correction of high postkeratoplasty ametropia in patients with keratoconus.
Methods
Seven eyes of 7 keratoconus patients postkeratoplasty (5 M, 2 F; mean age 34.1±5.9 years, range 28–44) unable to wear glasses or contact lenses were included in the study. A foldable phakic posterior chamber Collamer toric lens was injected through a standard 3.0-mm clear corneal temporal incision. Uncorrected distance visual acuity (UCDVA, logMAR), best-corrected distance visual acuity (BCDVA, logMAR), spherical refraction, cylindrical refraction, and refractive spherical equivalent (RSE) were measured preoperatively and postoperatively. Postoperative adverse events were recorded.
Results
The mean follow-up was 12.8±8.8 months (range 4–30). A significant (p<0.01) improvement was observed postoperatively in mean UCDVA (1.18±0.4 vs 0.2±0.1), spherical refraction (-5.89±3.43 vs 0.53±0.75), cylindrical refraction (-4.39±0.75 vs −1.74±0.84), and RSE (-8.09±3.77 vs −0.33±0.54). The BCDVA changes were not significant (0.09±0.11 vs 0.05±0.08). All patients gained ≥5 lines of UCDVA (average 7.6±1.9 lines). The number of patients with UCDVA ≥6/12 (0.3 logMAR) increased after surgery (0% vs 87.5%; p<0.01), while the number of patients with BCDVA ≥6/12 was unchanged (100% vs 100%; NS), with 0% (0/7) of patients losing ≥2 BCDVA lines. No complications were observed postoperatively.
Conclusions
Toric implantable Collamer lens was safe and effective in correcting postkeratoplasty myopia and astigmatism in keratoconus patients.
Get full access to this article
View all access options for this article.